Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Exenatide - Intarcia Therapeutics/IQVIA/Servier

Drug Profile

Exenatide - Intarcia Therapeutics/IQVIA/Servier

Alternative Names: Exenatide in DUROS®; Exenatide intravenous - Intarcia Therapeutics/IQVIA/Servier; Exenatide subcutaneous implant - Intarcia Therapeutics/IQVIA/Servier; Exendin-4; ITCA-650

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Intarcia Therapeutics
  • Class Antihyperglycaemics; Obesity therapies; Peptides; Venoms
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preregistration Type 2 diabetes mellitus

Most Recent Events

  • 28 Aug 2023 i2o Therapeutics acquires Exenatide from Intarcia Therapeutics
  • 03 Sep 2021 No development reported - Phase-III for Type 2 diabetes mellitus (Adjunctive treatment) in Netherlands, Canada, Sweden, Turkey, Czech Republic, South Africa, Slovakia, Romania, Croatia, Poland, Spain, Bulgaria, Germany, Finland, Estonia, Hungary, Latvia, Denmark (SC)
  • 08 Oct 2019 Intarcia resubmits NDA to US FDA for Type 2 diabetes mellitus
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top